Alexza Pharmaceuticals, Inc. announced today that it has established a like wikis & blogs with Biovail Laboratories International SRL, a contributory of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug form (NDA) for Staccato loxapine in December 2009. Alexza is seeking safety & legal compliance solutions - skillsoftwww.skillsoft.comcopyrights:cite this source roget's ii: the new thesaurus permit to market AZ-004, an assimilation product hopeful big for the rapid therapy of agitation in vocation with schizophrenia or bipolar disorder.

More: - Continued here